



Medical Policies



Policy Number: S-124

Policy Name: Kidney Transplant

Policy Type: Medical

Effective Date: 09-15-2025

Policy Subtype: Surgery

End Date: 11-02-2025

Description

Kidney transplant, a treatment option for end-stage renal disease, involves the surgical removal of a kidney from a cadaver, living-related donor, or living-unrelated donor and transplantation into the recipient.

Policy Application

All claims submitted for this policy will be processed according to the policy effective date and associated revision effective dates in effect on the date of service.

NoSuchKey The specified key does not exist.policies/bcbsnd/S-124/v019aB/criteriaText.txtAW0PVV2Y0YNNVQ08Lq6m0o4PimyzJxGzWrrRN23vScBXwfBGPIZBJydPLhJP7THvFuHt25g/5AP3GppAuqlixpQlOgA=NoSuchKey The specified key does not exist.policies/bcbsnd/S-124/vv019ab/content.txtAW0XE11DT16H918MIEhKTDsjynz5CpaR2FiHUK6jxDejkLUaWysismiJoPc3EU+9TSogmDckXJP8gar+Wc9opEwR6SU=

Diagnosis Codes

N18.4	N18.5	N18.6	N18.9
-------	-------	-------	-------

CURRENT CODING

CPT:

50300	DONOR NEPHRECTOMY CADAVER DONOR UNI/BILATERAL	Commercial
50320	DONOR NEPHRECTOMY OPEN LIVING DONOR	Commercial
50323	BKBENCH PREPJ CADAVER DONOR RENAL ALLOGRAFT	Commercial
50325	BKBENCH PREPJ LIVING RENAL DONOR ALLOGRAFT	Commercial
50327	BKBENCH RCNSTJ RENAL ALGRFT VENOUS ANAST EA	Commercial
50328	BKBENCH RCNSTJ RENAL ALLOGRAFT ARTERIAL ANAST EA	Commercial
50329	BKBENCH RCNSTJ ALGRFT URETERAL ANAST EA	Commercial

50340	RECIPIENT NEPHRECTOMY SEPARATE PROCEDURE	Commercial
50360	RENAL ALTRNSPLJ IMPLTJ GRF W/O RCP NEPHRECTOMY	Commercial
50365	RENAL ALTRNSPLJ IMPLTJ GRF W/RCP NEPHRECTOMY	Commercial
50370	REMOVAL OF TRANSPLANTED RENAL ALLOGRAFT	Commercial
50380	RENAL AUTOTRANSPLANTATION REIMPLANTATION KIDNEY	Commercial
50547	LAPAROSCOPY DONOR NEPHRECTOMY LIVING DONOR	Commercial
50300	DONOR NEPHRECTOMY CADAVER DONOR UNI/BILATERAL	Medicaid Expansion
50320	DONOR NEPHRECTOMY OPEN LIVING DONOR	Medicaid Expansion
50323	BKBENCH PREPJ CADAVER DONOR RENAL ALLOGRAFT	Medicaid Expansion
50325	BKBENCH PREPJ LIVING RENAL DONOR ALLOGRAFT	Medicaid Expansion
50327	BKBENCH RCNSTJ RENAL ALGRFT VENOUS ANAST EA	Medicaid Expansion
50328	BKBENCH RCNSTJ RENAL ALLOGRAFT ARTERIAL ANAST EA	Medicaid Expansion
50329	BKBENCH RCNSTJ ALGRFT URETERAL ANAST EA	Medicaid Expansion
50340	RECIPIENT NEPHRECTOMY SEPARATE PROCEDURE	Medicaid Expansion
50360	RENAL ALTRNSPLJ IMPLTJ GRF W/O RCP NEPHRECTOMY	Medicaid Expansion
50365	RENAL ALTRNSPLJ IMPLTJ GRF W/RCP NEPHRECTOMY	Medicaid Expansion
50370	REMOVAL OF TRANSPLANTED RENAL ALLOGRAFT	Medicaid Expansion
50380	RENAL AUTOTRANSPLANTATION REIMPLANTATION KIDNEY	Medicaid Expansion
50547	LAPAROSCOPY DONOR NEPHRECTOMY LIVING DONOR	Medicaid Expansion

References

1. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC. Organ Procurement and Transplantation Network Policies. 2020; <https://optn.transplant.hrsa.gov>.
2. National Kidney Foundation. Glomerular Filtration Rate (GFR). n.d.; <https://www.kidney.org/atoz/content/gfr>.
3. American Society of Transplant Surgeons (ASTS), The American Society of Transplantation (AST), The Association of Organ Procurement Organizations (AOPO), et al. Statement on transplantation of organs from HIV-infected deceased donors.
4. Kervinen, MG, Lehto S, Helve J, et al. Type 2 diabetic patients on renal replacement therapy: Probability to receive renal transplantation and survival after transplantation. *PLoS One*. 2018 15;13(8):e0201478.
5. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. *Ann Transl Med*. 2018;6(20):409.
6. Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta analysis. *BMJ*. 2022;376:e068769.
7. Zheng X, Gong L, Xue W, et al. Kidney transplant outcomes in HIV-positive patients: A systematic review and meta-analysis. *AIDS Res Ther*. 2019;16(1):37.
8. Kainz A, Kammer M, Reindl-Schwaighofer R, et al. Waiting time for second kidney transplantation and mortality. *Clin J Am Soc Nephrol*. 2022;17(1):90- 97.
9. Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis c infected kidneys into uninfected recipients: A single- group trial. *Ann Intern Med*. 2018;169(5):273-281.
10. Durand CM, Bowering MG, Brown DM, et al. Direct-Acting antiviral prophylaxis in kidney transplantation from hepatitis c virus-infected donors to noninfected recipients: An open-label nonrandomized trial. *Ann Intern Med*. 2018;168(8):533-540.
11. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis c-infected kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis c virus infection. *J Am Soc Nephrol*. 2020;31(11):2678- 2687.
12. Sise ME, Goldberg DS, Schaubel DE, et al. One-year outcomes of the multi- center study to transplant hepatitis c-infected kidneys (MYTHIC) Trial. *Kidney Int Rep*. 2021;7(2):241-250.
13. Gupta G, Yakubu I, Bhati CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. *Am J Transplant*. 2020;20(3):739-751.

14. Franco A, Moreso F, Merino E, et al. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: A prospective study. *Transpl Int*. 2019;32(7):710-716.
15. Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience. *Hepatology*. 2020;72(1):32-41.
16. Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, openlabel study [published correction appears in *Lancet Gastroenterol Hepatol*. 2020 Jul;5(7):e6]. *Lancet Gastroenterol Hepatol*. 2020;5(7):649-657.
18. Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. *Am J Transplant*. 2019;19(11):3046-3057.
20. Friebus-Kardash J, Gäckler A, Kribben A, et al. Successful early sofosbuvir- based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. *Transpl Infect Dis*. 2019;21(5):e13146.
21. Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience. *Transpl Infect Dis*. 2021;23(3):e13540.
22. Alghamdi W, Lotfy K, Weernink C, et al. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: Ready for prime time. *BMC Gastroenterol*. 2022;22(1):34.
23. Kainz A, Kammer M, Reindl-Schwaighofer R, et. al. Waiting time for second kidney transplantation and mortality. *Clin zJ Am Soc Nephrol*. 2022; 17(1): 90- 97.
24. Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta-analysis. 2022; 1;376:e068769.

ND Committee Review

Internal Medical Policy Committee 1-19-2021 Adopting Policy *Effective March 1, 2021*

Internal Medical Policy Committee 1-20-2022 Annual Review *Effective March 7, 2022*

Internal Medical Policy Committee 11-29-2022 Revision- *Effective January 02, 2023*

- *Updated* policy language

Internal Medical Policy Committee 5-23-2023 Annual Review *Effective July 3, 2023*

Internal Medical Policy Committee 5-14-2024 Annual Review *Effective July 1, 2024*

- *Added* Policy Application

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.